Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq.
Open accessPreprint — published as 10.22578/ijms.19.1.14 · Paper page
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Objectives: COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try repurposed old drugs on COVID-19. Methods: Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug/kg PO of Ivermectin per day for 2-3 days along with 100mg PO doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy. The time to recovery, the progression of the disease, and the mortality rate were the outcome-assessing parameters. Results: among all patients and among severe patients, 3/70 (4.28%) and 1/11 (9%), respectively progressed to a more advanced stage of the disease in the Ivermectin-Doxycycline group versus 7/70 (10%) and 7/22 (31.81%), respectively in the control group (P>0.05). The mortality rate was 0/48 (0%), 0/11 (0%), and 2/11 (18.2%) in mild-moderate, severe, and critical COVID-19 patients, respectively in Ivermectin-Doxycycline group versus 0/48 (0%), and 6/22 (27.27%) in mild-moderate and severe COVID-19 patients, respectively in standard therapy group (p=0.052). Moreover, the mean time to recovery was 6.34, 20.27, and 24.13 days in mild-moderate, severe, and critical COVID-19 patients, respectively in Ivermectin-Doxycycline group versus 13.66 and 24.25 days in mild-moderate and severe COVID-19 patients, respectively in standard therapy group (P<0.01). Conclusions: Ivermectin with doxycycline reduced the time to recovery and the percentage of patients who progress to more advanced stage of disease; in addition, Ivermectin with doxycycline reduced mortality rate in severe patients from 22.72% to 0%; however, 18.2% of critically ill patients died with Ivermectin and doxycycline therapy. Taken together, the earlier administered Ivermectin with doxycycline, the higher rate of successful therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lastly, a study by Hashim et al. from Iraq provided insufficient details on the randomization process, had a lack of clarity on participants who were analyzed, and involved unblinded assessment of a subjective outcome [10].”
From Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179 · cited 3×
“Ivermectin reduced viral load of SARS-CoV-2 in vitro by 5000 folds within 48 h (7).”
BackgroundCoronavirus Disease 2019–COVID-19
Dhama, K., Khan, S., Tiwari, R., Sircar, S., Bhat, S., Malik, Y. S., Singh, K. P., Chaicumpa, W., Bonilla-Aldana, D. K., & Rodriguez-Morales, A. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00028-20 · Cited by 1,876 · cited 2×
“Almost all patients start as mild-moderate disease; however, about 15% of them progress within 5-14 days post infection to a more advanced stage of the disease, being severe and critical patients [2].”
Background(2020) · Nature Communications · doi:10.1101/2020.04.14.20065771 · Cited by 1,019
Wagstaff, K. M., Sivakumaran, H., Heaton, S. M., Harrich, D., & Jans, D. A. (2012) · Biochemical Journal · doi:10.1042/bj20120150 · Cited by 680 · cited 6×
“of several viruses such as HIV-1, Zika and dengue viruses (10).”
BackgroundMethodInfluentialSARS-CoV-2 viral load predicts COVID-19 mortality
Pujadas, E., Chaudhry, F., McBride, R., Richter, F., Zhao, S., Wajnberg, A., Nadkarni, G., Glicksberg, B. S., Houldsworth, J., & Cordon-Cardo, C. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30354-4 · Cited by 534
SARS-CoV-2 viral load predicts COVID-19 mortality
Pujadas, E., Chaudhry, F. F., McBride, R. B., et al. (2020) · medRxiv · doi:10.1101/2020.06.11.20128934 · Cited by 478 · cited 1×
“It has been found that most of COVID-19 patients who progress to severe/critical disease have high viral load of SARS-CoV-2 and over-reacting immune response (24).”
BackgroundIvermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
Heidary, F., & Gharebaghi, R. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0336-z · Cited by 435 · cited 6×
“This explains how Ivermectin could alleviate symptoms of COVID-19 patients at viral replication phase (the first 7-10 days of infection) as well as the later hyperinflammatory phase [7-10].”
BackgroundInfluentialExpression of the Zinc-Finger Antiviral Protein Inhibits Alphavirus Replication
Bick, M. J., Carroll, J.-W. N., Gao, G., Goff, S. P., Rice, C. M., & MacDonald, M. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.21.11555-11562.2003 · Cited by 384 · cited 3×
“Both drugs are FDA approved and have a high historical safety record [8,10,16, 19]; moreover, no interaction is known between Ivermectin and Doxycycline or between Ivermectin-Doxycycline and any of the medications given in the standard care.”
BackgroundRajter, J. C., Sherman, M. S., Fatteh, N., Vogel, F., Sacks, J., & Rajter, J.-J. (2021) · Chest · doi:10.1016/j.chest.2020.10.009 · Cited by 318
A brief-review of the risk factors for covid-19 severity
Rod, J. E., Oviedo-Trespalacios, O., & Cortes-Ramirez, J. (2020) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2020054002481 · Cited by 232
Cited by
López-Medina, E., López, P., Hurtado, I. C., Dávalos, D. M., Ramirez, O., Martínez, E., Díazgranados, J. A., Oñate, J. M., Chavarriaga, H., Herrera, S., et al. (2021) · JAMA · doi:10.1001/jama.2021.3071 · Cited by 376
Kory, P., Meduri, G. U., Varon, J., Iglesias, J., & Marik, P. E. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001377 · Cited by 203
Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001402 · Cited by 264
Ivermectin for preventing and treating COVID-19
Popp, M., Reis, S., Schießer, S., Hausinger, R. I., Stegemann, M., Metzendorf, M.-I., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015017.pub3 · Cited by 169
A review of potential suggested drugs for coronavirus disease (COVID-19) treatment
Tarighi, P., Eftekhari, S., Chizari, M., Sabernavaei, M., Jafari, D., & Mirzabeigi, P. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173890 · Cited by 140
“Ivermectin group had less progression to more advanced disease and mortality rate, also significantly decreased time to recovery (Hashim et al., 2020).”
Metadata
- Authors
- Hashim, H. A., Maulood, M. F., Rasheed, A. M., Fatak, D. F., Kabah, K. K., & Abdulamir, A. S.
- Affiliations
- Baghdad Medical City (IQ)
- Ministry of Health (IQ)
- Nahrain University (IQ)
- ORCID
- Hashim, Hashim A.
- Venue
- Iraqi journal of Medical Sciences
- Publisher
- openRxiv
- Published
- 2020-10-27
- Volume
- 19
- Issue
- 1
- ISSN
- 1681-6579 (ISSN-L)
- OpenAlex
- W4287129885
- Cited by
- 98
- References
- 26
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 5 · 2022: 25 · 2021: 51 · 2020: 9
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Iraqi journal of Medical Sciences (publishedVersion, cc-by-nc-nd)
- medRxiv (acceptedVersion, cc-by-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Keywords
- COVID-19 pandemic, ivermectin, doxycycline, drug repurposing, combination therapy, disease progression, mortality, time to recovery, severe COVID-19, critical COVID-19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq. https://app.cochat.ai/papers/10.1101/2020.10.26.20219345
- The paper
- Hashim, H. A., Maulood, M. F., Rasheed, A. M., Fatak, D. F., Kabah, K. K., & Abdulamir, A. S. (2020). Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq. Iraqi journal of Medical Sciences. https://doi.org/10.1101/2020.10.26.20219345
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.